Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04056247 · ClinicalTrials.gov registry record

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

A clinical trial of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer, sponsored by OncoHost.

Active
Registry status
10,000
Enrollment target
20
Study locations

NCT04056247 is a study of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer that is active but no longer recruiting, run by OncoHost. The registered enrollment target is 10,000 participants, above the 255-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (3822% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04056247, a study of Stage IV Non-small Cell Lung Cancer and Stage IV Small Cell Lung Cancer, is active but no longer recruiting, sponsored by OncoHost.

ACTIVE NOT RECRUITING
Registry status
10,000 participants
Enrollment target
20
Study locations

Study Summary

The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.

Interventions

  • OTHER Plasma sample collection

Study Locations (20)

Other

  • Asklepois - Gauting
  • Thoraxklinik Heidelberg gGmbH - Heidelberg
  • Haemek Medical Center - Afula
  • Barzilai Medical Center - Ashkelon
  • Soroka Medical Center - Beersheba
  • Shamir Medical Center - Be’er Ya‘aqov
  • Bnai Zion Medical Center - Haifa
  • Rambam Medical Center - Haifa

Florida

  • Mayo Clinic - Jacksonville
  • University of Miami - Miami
  • Florida Cancer Specialist and Research Institute - Orlando
  • Protean Biodiagnosics - Orlando

Texas

  • Michael E. Debakey VA Medical Center - Houston
  • 151-Christus Health St. Michael - Texarkana

Alabama

  • Birmingham VAHCS - Birmingham

Illinois

  • Northwest Community Healthcare - Rolling Meadows

Iowa

  • Helen Nassif Community Cancer Center - Cedar Rapids

New Jersey

  • Rutgers Cancer Institute - New Brunswick

New York

  • Roswell Park - Buffalo

Trial Details

FieldValue
Enrollment Target 10,000 participants
Start Date 2019-10-01
Est. Completion 2029-10-01

Sponsor

OncoHost

2 total trials

What the Registry Record Tells You About NCT04056247

The ClinicalTrials.gov registry entry for NCT04056247 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 10,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 23 other Stage IV Non-small Cell Lung Cancer trials with a reported enrollment target (3822% higher). The listed sponsor is OncoHost, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Stage IV Non-small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Plasma sample collection is the first listed.

NCT04056247 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT04056247 about?

NCT04056247 is a clinical study titled "Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments". The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatme...

What is the current status of trial NCT04056247?

This trial is currently active not recruiting. The enrollment target is 10,000 participants. The study started on 2019-10-01. Estimated completion is 2029-10-01.

What conditions does trial NCT04056247 study?

This clinical trial studies the following conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma.

What interventions are being tested in trial NCT04056247?

The interventions under investigation include: Plasma sample collection (OTHER).

Who is sponsoring clinical trial NCT04056247?

This trial is sponsored by OncoHost, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04056247 being conducted?

This trial has 20 study locations across Alabama, Florida, Illinois, Iowa, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage IV Non-small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.